Authors

Marj P. Zimmerman, BSPharm, MS, Stanton R. Mehr

Latest:

Supportive Care in Oncology Therapy: Pegfilgrastim Biosimilars in the Pipeline

Pegylated version (pegfilgrastim) Neulasta® is the more commonly prescribed agent, with a significantly longer half-life than its predecessor and is the preferred in patients receiving cancer chemotherapy.

The Center for Biosimilars Staff

Latest:

Webinar: Streamlining the Regulatory Process to Advance Access to Biosimilars

This webinar celebrating Global Biosimilars Week was hosted by The Center for Biosimilars® in partnership with the International Generics and Biosimilars Association.

Jaime Rosenberg

Latest:

Part D Beneficiaries May Pay More for Some Generics, Biosimilars Than Brand-Name Drugs

Medicare Part D enrollees may actually pay more for some generic drugs than they would for their brand-name counterparts because of the Part D benefit, according to findings of a new study appearing in Health Affairs.

Nancy J. Globus, PharmD

Nancy J. Globus, PharmD, is Vice President of Regulatory Affairs for the Accreditation Council for Medical Affairs, based in Oradell, New Jersey. Nancy focuses on helping the industry build error prevention into products by evaluating proposed names and labels prior to regulatory approval. In her 20-year medication safety career, she has reviewed thousands of names for submission to FDA, European Medicines Agency, and Health Canada. In addition to medication safety, she is passionate about patient advocacy and community pharmacy. You can find her at www.medicalaffairsspecialist.org/approve or on Twitter @MedSafetyGal.

Latest:

Alphabet Soup: The Story Behind Biosimilar Nonproprietary Name Suffixes

Theodore Bosworth

Latest:

Phase 3 Study Confirms Clinical Equivalence for ABP 980 and Reference Trastuzumab

Complete phase 3 data show that a biosimilar almost beat reference trastuzumab (Herceptin) for the primary endpoint of pathologic complete response in patients with HER2-positive early breast cancer.

Sarfaraz K. Niazi, PhD

Sarfaraz K. Niazi, PhD, is an adjunct professor of biopharmaceutical sciences at the University of Illinois and the University of Houston, and founder of biosimilars companies Karyo Biologics and Adello Biologics. He also founded the biosimilar advisory company PharmSci.

Latest:

BioRationality: A Proposal to Create a New Association With Rational Scientific Agenda

Samantha DiGrande

Latest:

AAM's Christine Simmon on Biosimilars Council Initiatives and Educating Around Interchangeability

After the Association for Accessible Medicines’ (AAM’s) Access! 2019 annual meeting came to a close last week, The Center for Biosimilars® spoke with Christine Simmon, senior vice president of policy and strategic alliances, AAM, and executive director, AAM’s Biosimilars Council, to get her take on some of the outcomes of the meeting.

Latest:

Rituximab Induction Is Cost Effective for Asymptomatic Advanced Follicular Lymphoma

Rituximab induction therapy has the highest probability of cost effectiveness in treating newly diagnosed patients with asymptomatic advanced follicular lymphoma, according to a study published in the British Journal of Haematology.

Advertisement

Advertisement